Stem-cell therapies in orthopedic rheumatology offer dual promise: immunomodulation and tissue repair. This editorial reviews 2023-2025 evidence across key rheumatic diseases, identifying where clinical signals are strongest. Mesenchymal stromal/stem cells (MSCs) show encouraging immunologic and symptomatic benefits in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), particularly lupus nephritis, with acceptable short-term safety. However, trial heterogeneity in MSC source, dose, and manufacturing limits reproducibility.
Source: ResearchGate
